EY 128
Alternative Names: Ethacrynate sodium; XaranoLatest Information Update: 18 May 2001
At a glance
- Originator Occupational Health & Rehabilitation
- Class Eye disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Miosis
Most Recent Events
- 18 May 2001 Profile reviewed but no significant changes made
- 13 Sep 2000 Discontinued-III for Eye surgery in USA (Unknown route)
- 13 Sep 2000 Discontinued-III for Miosis in USA (Unknown route)